干扰素-α联合雷利度胺对多发性骨髓瘤细胞的增殖抑制作用研究  

Study on The Effect of IFN-α plus Lenalidomide in Inhibiting the Proliferation of Multiple Myeloma Cells in vitro

作　　者：商安芳[1] 陈同娇[1] 郭静明[1] 朱磊[1] 田铭[1] 

机构地区：[1]三峡大学第一临床医学院宜昌市中心人民医院,宜昌443003

出　　处：《中国医药导刊》2013年第1期141-142,137,共3页Chinese Journal of Medicinal Guide

摘　　要：目的:探讨干扰素联合雷利度胺对多发性骨髓瘤细胞的增殖抑制作用。方法:实验分为3组:干扰素联合雷利度胺组(IFN+LEN组),各孔培养基中添加100μg/L雷利度胺和200 U/ml干扰素-α,雷利度胺组(LEN组),各孔培养基中添加100μg/L雷利度胺;对照组(CTL组),U266细胞正常培养。分别分析共培养的U266细胞的增殖水平、细胞周期以及促瘤因子血管内皮生长因子(VEGF)和碱性成纤维细胞生长因子(bFGF)的表达水平。结果:干扰素联合雷利度胺可以较显著抑制人骨髓瘤细胞U266的增殖,诱导U266细胞的周期停滞,并能显著抑制促瘤细胞因子血管内皮生长因子和碱性成纤维细胞生长因子的表达水平。结论:干扰素联合雷利度胺在抑制人骨髓瘤细胞中具有潜在价值。Objective：To study on the effect of IFN-α plus lenalidomide in inhibiting the proliferation of multiple myeloma cells in vitro.Methods：Multiple myeloma cells U266 were cultured and incubated with IFN-α plus lenalidomide（each at a dosage of 200U/ ml and 100μg/L）,lenalidomide alone（100μg/L）,and placebo（as a control group）.Proliferation,cell cycle,and the expression of VEGF and bFGF of U266 were evaluated after a period of co-culture.Results：Compared with the other two groups,the treatment of IFN-α plus lenalidomide were better able to inhibit the proliferation of U266 cells,induce the cycle arrest of U266,and reduce the levels of VEGF and bFGF expression in the cells.Conclusion：IFN-α plus lenalidomide can play a potential role in treating with multiple myeloma cells.

关 键 词：雷利度胺 干扰素-Α 多发性骨髓瘤 抑制 

分 类 号：R733.3[医药卫生—肿瘤]